<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04105699</url>
  </required_header>
  <id_info>
    <org_study_id>AB-PSP-002</org_study_id>
    <nct_id>NCT04105699</nct_id>
  </id_info>
  <brief_title>Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis</brief_title>
  <official_title>A Multicenter, Prospective, Biomarker-result-blinded Observational Study Evaluating Immunoassay Measurements of Pancreatic Stone Protein Performed on Abionic's abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abionic SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Biomedical Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ocean State Clinical Coordinating Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abionic SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, biomarker-result-blinded observational study evaluating&#xD;
      immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE&#xD;
      device with the PSP assay on adult ICU patients at risk of sepsis as an aid in identifying&#xD;
      sepsis. Participants will be followed for the development of infection and sepsis until&#xD;
      discharge from ICU or death or until day 7 (or day 15 of ICU if participant diagnosed with&#xD;
      ICU-acquired infection or sepsis during the first 7 days), whatever comes first.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 27, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of the abioSCOPE PSP assay performed on day 1 of a participant's ICU admission to correctly identify those with sepsis.</measure>
    <time_frame>Day 1</time_frame>
    <description>Assess the clinical sensitivity and specificity of the abioSCOPE PSP assay obtained on day 1 of ICU stay to identify sepsis, based on EIRC assessment of sepsis.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Diagnostic performance assessment of the abioSCOPE PSP assay performed on day 1 and daily, together with other laboratory data and clinical assessments, to correctly identify sepsis from infection-negative or infection-positive systemic inflammation</measure>
    <time_frame>Day 1 to Day 7 (or day 15 if ICU-acquired infection or sepsis during first 7 days) or until discharge from ICU</time_frame>
    <description>Sensitivity, specificity, positive and negative predictive values of the abioSCOPE PSP assay obtained on day 1 and daily up to day 7 (or day 15 if ICU-acquired infection or sepsis during first 7 days) of ICU stay to identify sepsis, based on EIRC assessment of sepsis.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">417</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Device: Blood sampling</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Daily blood sample which will be taken for the PSP measurement using the abioSCOPE as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein [CRP] and Procalcitonin [PCT]).</description>
    <arm_group_label>Device: Blood sampling</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      venous serum retained for future investigation related to sepsis biomarkers&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ICU admitted patients at risk of developing sepsis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Provision and understanding of signed and dated written informed consent by patient&#xD;
             or legally designated representative prior to any mandatory study-specific procedures,&#xD;
             sample collection, or analysis.&#xD;
&#xD;
          -  2. Male or female, aged ≥ 18 years.&#xD;
&#xD;
          -  3. Admitted to ICU on the day of screening, with expectation that patient will require&#xD;
             ICU management for a minimum of 24 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Expected to die within 24 hours no matter what therapy is given, from the time of&#xD;
             screening.&#xD;
&#xD;
          -  2. Suffering on ICU admission or study entry from or known acute or chronic&#xD;
             pancreatitis or pancreatic cancer).&#xD;
&#xD;
          -  3. Admitted to ICU due to elective cardiac surgery with an uncomplicated stay&#xD;
             anticipated.&#xD;
&#xD;
          -  4. Patients having a valid Do Not Resuscitate order.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BayState Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health St. Vincent</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Pancreatic Stone Protein</keyword>
  <keyword>Point-of-care device</keyword>
  <keyword>Immunoassay</keyword>
  <keyword>Intensive care unit</keyword>
  <keyword>Abionic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

